3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
27
Carcinoma, Hepatocellular
26
Small Cell Lung Carcinoma
17
Lung Neoplasms
15
Neoplasms
13
Breast Neoplasms
8
Colorectal Neoplasms
7
Carcinoma, Renal Cell
7
Squamous Cell Carcinoma of Head and Neck
6
Melanoma
6
Uterine Cervical Neoplasms
5
Urinary Bladder Neoplasms
5
Triple Negative Breast Neoplasms
5
Neoplasm Metastasis
5
Carcinoma, Transitional Cell
5
Prostatic Neoplasms
4
Glioblastoma
4
Stomach Neoplasms
3
Solid Tumors
3
Sarcoma, Alveolar Soft Part
3
Sarcoma
3
Liver Neoplasms
3
Extensive Stage Lung Small Cell Carcinoma
3
Carcinoma
3
Treatment-Refractory Solid Tumors
2
Small Cell Lung Cancer Extensive Stage
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Osteosarcoma
2
Nasopharyngeal Carcinoma
2
Interventions
Cisplatin
14
Paclitaxel
12
pembrolizumab
9
Fluorouracil
7
Radiotherapy
6
Irinotecan
5
Esophagectomy
5
tislelizumab
4
Oxaliplatin
4
Leucovorin
4
Drug Therapy
4
Carboplatin
4
toripalimab
3
Levoleucovorin
3
Docetaxel
3
Capecitabine
3
camrelizumab
2
Taxes
2
Radiation
2
Nivolumab
2
Injections
2
130-nm albumin-bound paclitaxel
2
spartalizumab
1
sintilimab
1
palbociclib
1
nimotuzumab
1
nazartinib
1
lenvatinib
1
ivarmacitinib
1
futibatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Squamous Cell Carcinoma
×
atezolizumab
×
90 days
×
Clear all
NCT04543617
2026-04-17
SKYSCRAPER-07
Hoffmann-La Roche
Phase 3
Active not recruiting
760 enrolled